RxDoctor Payments Data

Nathan Kung, MD

Neurology · Lone Tree, CONPI 1093000960

Payments from drug & device makers

$17,223in general payments, 2019–2025

Across 923 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$1K
  • Lilly USA, LLC$969
  • Amgen$945
  • EMD Serono, Inc.$828
  • Teva Pharmaceuticals USA, Inc.$729
  • plus $9K from 49 others

What the payments were for

  • Food & beverage$17,196100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,223 in reported general payments places this provider in the 70th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$185,704
Medicare patients
73
Services billed
17,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4626$271,968
Nurtec OdtRimegepant Sulfate82$127,577
UbrelvyUbrogepant51$82,335
BriviactBrivaracetam28$52,464
QuliptaAtogepant33$49,655
ReyvowLasmiditan Succinate34$29,883
Ajovy AutoinjectorFremanezumab-Vfrm14$28,693
OzempicSemaglutide14$28,357
Emgality PenGalcanezumab-Gnlm25$26,679
EliquisApixaban16$25,241
MounjaroTirzepatide15$21,667
MyrbetriqMirabegron18$11,006
BelbucaBuprenorphine Hcl13$6,296
Diclofenac Potassium38$4,736
Buprenorphine12$3,344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Eliquis$394$152,81798 claims
AbbVieUbrelvy, Qulipta$3,402$131,99084 claims
UCB, Inc.Briviact$1,094$52,46428 claims
Lilly USA, LLCReyvow, Mounjaro$969$51,55149 claims
Collegium Pharmaceutical, Inc.Belbuca$46$6,29613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 334 neurology providers in Colorado.

Other neurology in Lone Tree

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →